NTHI Stock Overview
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Neonc Technologies Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.50 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTHI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | 0.5% | 2.7% |
| 1Y | n/a | 3.4% | 26.0% |
Return vs Industry: Insufficient data to determine how NTHI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NTHI performed against the US Market.
Price Volatility
| NTHI volatility | |
|---|---|
| NTHI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTHI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NTHI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 8 | Thomas Chen | www.neonctech.com |
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Neonc Technologies Holdings, Inc. Fundamentals Summary
| NTHI fundamental statistics | |
|---|---|
| Market cap | US$282.00m |
| Earnings (TTM) | -US$14.92m |
| Revenue (TTM) | US$70.46k |
4,002x
P/S Ratio-18.9x
P/E RatioIs NTHI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTHI income statement (TTM) | |
|---|---|
| Revenue | US$70.46k |
| Cost of Revenue | US$2.74m |
| Gross Profit | -US$2.67m |
| Other Expenses | US$12.25m |
| Earnings | -US$14.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | -3,785.46% |
| Net Profit Margin | -21,176.05% |
| Debt/Equity Ratio | -47.2% |
How did NTHI perform over the long term?
See historical performance and comparison